{"id":24163,"date":"2026-07-01T11:33:03","date_gmt":"2026-07-01T09:33:03","guid":{"rendered":"https:\/\/faesfarma.com\/faes-farma-avanza-internacionalizacion-acuerdo-comercializar-nuevo-tratamiento-urologia-latinoamerica\/"},"modified":"2026-07-01T11:37:28","modified_gmt":"2026-07-01T09:37:28","slug":"faes-farma-advances-international-expansion-agreement-commercialise-new-urology-treatment-latin-america","status":"publish","type":"post","link":"https:\/\/faesfarma.com\/en\/faes-farma-advances-international-expansion-agreement-commercialise-new-urology-treatment-latin-america\/","title":{"rendered":"Faes Farma advances its international expansion through an agreement to commercialise a new urology treatment in Latin America"},"content":{"rendered":"<ul>\n<li><strong>The company has signed an exclusive licensing and supply agreement with Dongkook Pharmaceutical to register and commercialize Uresco in 13 Latin American countries.<\/strong><\/li>\n<\/ul>\n<ul>\n<li><strong>The agreement includes a total amount of up to EUR 2 million, linked to obtaining regulatory registrations and meeting commercial milestones that reflects both parties\u2019 commitment to the progressive development of Uresco across the region.<\/strong><\/li>\n<\/ul>\n<ul>\n<li><strong>The partnership enables Faes Farma to expand its portfolio in Latin America and reinforces its position as a partner of choice in this market.<\/strong><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>Bilbao, July 1st, 2026.<\/strong> &#8211; Faes Farma has signed an exclusive licensing and supply agreement with Dongkook Pharmaceutical for the commercialisation of Uresco in Latin America. Uresco is a fixed-dose combination of dutasteride and tadalafil indicated for the treatment of benign prostatic hyperplasia (BPH), one of the most common urological conditions affecting men over the age of 50.<\/p>\n<p>The licence, which will remain in force for ten years from the product\u2019s commercial launch, covers 13 Latin American countries, including Mexico, Colombia, Ecuador, Peru and Chile. Under the terms of the agreement, Dongkook Pharmaceutical will supply the finished product to Faes Farma, which will be responsible for its registration and commercialisation in the licensed territories.<\/p>\n<p>The collaboration includes an upfront payment, as well as additional milestone payments tied to regulatory approvals and commercial sales achievements, up to a total amount to EUR 2 million and a long-term revenue-sharing structure aligned with the commercial success of the product. This structure reflects the commitment of both companies to the progressive development of Uresco across Latin American markets.<\/p>\n<p>Benign prostatic hyperplasia is a non-cancerous enlargement of the prostate gland. It can have a significant impact on patients\u2019 quality of life, causing bothersome urinary symptoms that negatively affect their wellbeing. The condition represents a sizeable and growing market in Latin America, driven by its high prevalence, an ageing population and the need for new therapeutic alternatives. In this context, Faes Farma is adding a differentiated product to its portfolio, supported by clinical evidence and aligned with the needs of both specialists and patients.<\/p>\n<p>The agreement also reinforces Faes Farma\u2019s position in Latin America, a region that has become the Group\u2019s main driver of organic growth. The company\u2019s strategic presence in urology was previously strengthened through a collaboration agreement with Japanese pharmaceutical company Kyorin Pharmaceutical for the commercialisation of Uritos (imidafenacin), an innovative treatment for overactive bladder.<\/p>\n<p>The addition of Uresco further underlines Faes Farma\u2019s commitment to specialising in high-value urology solutions and strengthens its role as a partner of choice for international pharmaceutical companies seeking to develop commercial opportunities in the region.<\/p>\n<p><em>&#8220;In Latin America, we have a well-established network, regulatory expertise and a strong local presence. These capabilities enable us to support the development of innovative products and bring new therapeutic alternatives closer to patients and healthcare professionals. Through this agreement, we continue advancing towards our goal of being recognised as the leading Spanish pharmaceutical company on a global scale,&#8221;<\/em> said Eduardo Recoder, CEO of Faes Farma.<\/p>\n<p>Uresco was developed by Dongkook Pharmaceutical and is supported by a Phase III clinical trial involving 667 patients with 48 weeks of follow-up, which demonstrated its superiority over the respective monotherapies. Its benefits include rapid improvement of urinary symptoms, reduction in prostate volume and disease progression, as well as improvements in sexual function associated with BPH. The treatment was approved in South Korea in January 2025, and Faes Farma will now begin the regulatory processes required for its commercialisation in the Latin American markets covered by the agreement.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The company has signed an exclusive licensing and supply agreement with Dongkook Pharmaceutical to register and commercialize Uresco in 13 Latin American countries. The agreement includes a total amount of up to [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":22127,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[83],"tags":[],"class_list":["post-24163","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-economic-and-financial-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/faesfarma.com\/en\/wp-json\/wp\/v2\/posts\/24163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/faesfarma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/faesfarma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/faesfarma.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/faesfarma.com\/en\/wp-json\/wp\/v2\/comments?post=24163"}],"version-history":[{"count":3,"href":"https:\/\/faesfarma.com\/en\/wp-json\/wp\/v2\/posts\/24163\/revisions"}],"predecessor-version":[{"id":24166,"href":"https:\/\/faesfarma.com\/en\/wp-json\/wp\/v2\/posts\/24163\/revisions\/24166"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/faesfarma.com\/en\/wp-json\/wp\/v2\/media\/22127"}],"wp:attachment":[{"href":"https:\/\/faesfarma.com\/en\/wp-json\/wp\/v2\/media?parent=24163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/faesfarma.com\/en\/wp-json\/wp\/v2\/categories?post=24163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/faesfarma.com\/en\/wp-json\/wp\/v2\/tags?post=24163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}